Abeona Therapeutics (NASDAQ:ABEO) Upgraded at StockNews.com

Abeona Therapeutics (NASDAQ:ABEO) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Friday.

Several other equities research analysts also recently weighed in on ABEO. HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of Abeona Therapeutics in a report on Monday, November 25th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $18.00 target price on shares of Abeona Therapeutics in a research note on Tuesday, October 29th.

Abeona Therapeutics Stock Up 1.2 %

Shares of ABEO traded up $0.07 during midday trading on Friday, hitting $5.70. 210,374 shares of the company’s stock traded hands, compared to its average volume of 415,259. The company has a current ratio of 6.12, a quick ratio of 6.12 and a debt-to-equity ratio of 0.31. The stock has a market capitalization of $247.78 million, a price-to-earnings ratio of -2.12 and a beta of 1.44. Abeona Therapeutics has a 1 year low of $3.05 and a 1 year high of $9.01. The firm’s fifty day moving average is $6.18 and its 200-day moving average is $5.51.

Institutional Investors Weigh In On Abeona Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of ABEO. Geode Capital Management LLC increased its holdings in Abeona Therapeutics by 21.7% in the 3rd quarter. Geode Capital Management LLC now owns 465,317 shares of the biopharmaceutical company’s stock worth $2,942,000 after buying an additional 83,050 shares during the period. XTX Topco Ltd purchased a new stake in shares of Abeona Therapeutics in the 3rd quarter valued at $160,000. Jane Street Group LLC acquired a new stake in shares of Abeona Therapeutics in the third quarter worth $84,000. Western Standard LLC raised its holdings in shares of Abeona Therapeutics by 7.0% during the third quarter. Western Standard LLC now owns 1,698,097 shares of the biopharmaceutical company’s stock worth $10,732,000 after purchasing an additional 110,998 shares during the last quarter. Finally, Citigroup Inc. boosted its holdings in Abeona Therapeutics by 10.1% in the third quarter. Citigroup Inc. now owns 616,668 shares of the biopharmaceutical company’s stock valued at $3,897,000 after purchasing an additional 56,332 shares during the last quarter. Institutional investors and hedge funds own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.